Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation
Shuai Wang, Lei Han, Jungsoo Han, et al.
Nature Chemical Biology (2019) Vol. 15, Iss. 12, pp. 1223-1231
Open Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

PROTACs: An Emerging Therapeutic Modality in Precision Medicine
Dhanusha A. Nalawansha, Craig M. Crews
Cell chemical biology (2020) Vol. 27, Iss. 8, pp. 998-1014
Open Access | Times Cited: 336
Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy
Chi Zhang, Ziling Zeng, Dong Cui, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 316
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Xinyi Li, Wenchen Pu, Qingquan Zheng, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 188
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 172
Chemistries of bifunctional PROTAC degraders
Chao-Guo Cao, Ming He, Liguo Wang, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 16, pp. 7066-7114
Closed Access | Times Cited: 170
PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them
Dongha Kim, Hye Jin Nam
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8412-8412
Open Access | Times Cited: 71
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Jeremy M. Kelm, Deepti S. Pandey, Evan Malin, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 51
PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response
Chiho Kim, Xudong Wang, Yonghao Yu
eLife (2020) Vol. 9
Open Access | Times Cited: 99
Cytoplasmic PARP1 links the genome instability to the inhibition of antiviral immunity through PARylating cGAS
Fei Wang, Mengmeng Zhao, Boran Chang, et al.
Molecular Cell (2022) Vol. 82, Iss. 11, pp. 2032-2049.e7
Open Access | Times Cited: 49
A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer
Ge Li, Shanshan Lin, Zelei Yu, et al.
Biochemical Pharmacology (2022) Vol. 206, pp. 115329-115329
Closed Access | Times Cited: 40
A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs
Nikol A. Zografou-Barredo, Alex J. Hallatt, J. S. JUN. RICCI, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 88-89, pp. 117334-117334
Open Access | Times Cited: 34
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications
Yvette Drew, Frank T. Zenke, Nicola J. Curtin
Nature Reviews Drug Discovery (2024) Vol. 24, Iss. 1, pp. 19-39
Closed Access | Times Cited: 12
Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets
Can-Bin Fang, Hua-Tao Wu, Manli Zhang, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 61
Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers
Chao-Guo Cao, Jie Yang, Yong Chen, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 19, pp. 11012-11033
Closed Access | Times Cited: 61
A cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer
Danhui Ma, Yutian Zou, Yunxiang Chu, et al.
Theranostics (2020) Vol. 10, Iss. 8, pp. 3708-3721
Open Access | Times Cited: 51
Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA -mutated cancer
Peng Li, Yuanli Zhen, Chiho Kim, et al.
Science Advances (2023) Vol. 9, Iss. 43
Open Access | Times Cited: 20
Recent Progress in DNA Damage Response-Targeting PROTAC Degraders
Binbin Cheng, Xiaoting Fei, Zongbao Ding, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 9, pp. 6906-6921
Closed Access | Times Cited: 6
PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs
Marı́a Maneiro, Elena De Vita, Daniel Conole, et al.
Progress in medicinal chemistry (2021), pp. 67-190
Closed Access | Times Cited: 36
Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer
Chunlan Pu, Yu Tong, Yuanyuan Liu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 236, pp. 114321-114321
Closed Access | Times Cited: 27
Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy
Xiaopeng Peng, Wanyi Pan, Feng Jiang, et al.
Pharmacological Research (2022) Vol. 186, pp. 106529-106529
Closed Access | Times Cited: 24
The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
Jaromir Hunia, Karol Gawalski, Aleksandra Szredzka, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 23
Positioning Loss of PARP1 Activity as the Central Toxic Event in BRCA-Deficient Cancer
Nathan J. MacGilvary, Sharon B. Cantor
DNA repair (2024) Vol. 144, pp. 103775-103775
Open Access | Times Cited: 5
Small molecules that target the ubiquitin system
Hai Qiu Wu, D.A. Baker, Huib Ovaa
Biochemical Society Transactions (2020) Vol. 48, Iss. 2, pp. 479-497
Open Access | Times Cited: 36
Systems approach to rational combination therapy: PARP inhibitors
Chaoyang Sun, Yong Fang, Marilyne Labrie, et al.
Biochemical Society Transactions (2020) Vol. 48, Iss. 3, pp. 1101-1108
Open Access | Times Cited: 33
Light-Controllable PROTACs for Temporospatial Control of Protein Degradation
Jing Liu, Yunhua Peng, Wenyi Wei
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 30
Page 1 - Next Page

Scroll to top